Program: Fibrotic–Oncologic Microenvironment Modulation (FOM-02)
(Investor-Grade Drug Candidate | Platform Expansion Demonstration)
I. EXECUTIVE SUMMARY
Candidate ID:
SCF-API-002
Working Name:
FIBROVEX-02
Indication Class:
Fibrosis & Tumor Microenvironment (TME) Modulation
Therapeutic Type:
Multi-Target SCF Synergistic API Stack
Positioning
FIBROVEX-02 is a next-generation SCF-derived therapeutic system engineered to:
- Disrupt fibrotic tissue remodeling
- Reprogram tumor microenvironment signaling
- Restore immune surveillance and metabolic balance
A system-level therapy targeting structural, immune, and metabolic drivers of disease simultaneously.
II. TARGET INDICATIONS
Primary
- Pulmonary fibrosis
- Liver fibrosis (NASH-related)
- Solid tumor microenvironment modulation
Secondary (Expansion)
- Pancreatic cancer (fibrotic TME)
- Breast tumor stromal remodeling
- Chronic organ fibrosis syndromes
III. SCF TARGET MAPPING
Multi-System Fault Alignment
SCF Fault Node | Target Mechanism | Therapeutic Role |
ECM Scaffold Decay | Fibroblast activation inhibition | Structural normalization |
Immune Shift | TME immune suppression reversal | Immune reactivation |
Bioenergetic Collapse | Tumor metabolic disruption | Energy targeting |
Redox Imbalance | Oxidative stress modulation | Microenvironment stabilization |
IV. ACTIVE COMPONENT ARCHITECTURE
SCF Fibonacci Stack Design (1+1⇒3 Synergy Model)
Component Class | Candidate Type | SCF Role |
Anti-Fibrotic Agent | TGF-β pathway inhibitor | ECM remodeling control |
Immunomodulator | Checkpoint pathway modulator | Restore immune activity |
Metabolic Disruptor | Glycolysis inhibitor | Target tumor metabolism |
Redox Regulator | Antioxidant modulator | Stabilize oxidative environment |
Botanical Synergist | Polyphenolic compound | Enhance multi-pathway synergy |
V. MOLECULAR DESIGN (API CORE)
Lead Scaffold (Example)
Class:
TGF-β / SMAD Pathway Modulator
SMILES (Prototype Structure):
COC1=CC=C(C=C1)C2=NC=NC3=CC=CC=C23Mechanistic Targets
- TGF-β receptor inhibition
- SMAD signaling disruption
- Collagen deposition reduction
VI. MECHANISM OF ACTION (MoA)
Multi-Layer Mechanism
Layer | Action | Outcome |
Structural | Inhibit fibroblast activation | Reduce fibrosis |
Immune | Restore T-cell activity | Enhance tumor clearance |
Metabolic | Disrupt glycolysis | Limit tumor growth |
Redox | Normalize oxidative balance | Stabilize microenvironment |
VII. MECHANISM OF EFFECT (MeA)
System-Level Outcomes
- Reduced fibrotic tissue accumulation
- Reversal of tumor-supportive microenvironment
- Improved immune surveillance
- Decreased disease progression
VIII. SCF SYNERGY METRICS
Metric | Score (Projected) | Interpretation |
TSSM | 0.89 | Strong multi-system targeting |
HSV-F² | 0.85 | High synergy across pathways |
SV-EQ | 0.81 | Effective system stabilization |
MGIS | 0.88 | High gene-network modulation |
IX. PHARMACOKINETIC DESIGN
Delivery Strategy
- Targeted nanoparticle delivery
- Tissue-specific accumulation (fibrotic sites)
- Controlled release system
PK Objectives
- Enhanced tissue penetration
- Reduced off-target toxicity
- Sustained therapeutic concentration
X. RESISTANCE PREVENTION MODEL
SCF Multi-Pathway Strategy
- Simultaneous targeting of:
- Fibrotic signaling
- Immune suppression
- Metabolic pathways
Outcome
- Reduced tumor resistance
- Improved long-term efficacy
XI. BIOMARKER PANEL
System | Biomarkers |
Structural | Collagen, TGF-β levels |
Immune | CD8+ T-cell activity |
Metabolic | Lactate, glucose uptake |
Redox | ROS, antioxidant capacity |
XII. PRECLINICAL DEVELOPMENT PLAN
Phase 0 — Validation
- Fibroblast and TME cell assays
- Multi-omic pathway validation
Phase 1 — Animal Models
- Fibrosis models
- Solid tumor models
Phase 2 — IND Preparation
- Toxicology
- PK/PD modeling
XIII. CLINICAL DEVELOPMENT STRATEGY
Phase | Objective |
Phase I | Safety + dosing |
Phase II | Biomarker response |
Phase III | Clinical efficacy |
XIV. COMPETITIVE ADVANTAGE
Why FIBROVEX-02 is Differentiated
Traditional Oncology/Fibrosis Drugs | FIBROVEX-02 |
Single pathway targeting | Multi-system intervention |
High resistance rates | Resistance-aware design |
Limited microenvironment impact | Full TME modulation |
Narrow indication | Multi-disease potential |
XV. PLATFORM VALIDATION
Proof of SCF Scalability
With SYNAPTEX-01 and FIBROVEX-02:
- Two distinct disease classes
- Two different biological architectures
- One unified SCF design system
Demonstratesplatform-level therapeutic generation capability
XVI. INVESTOR POSITIONING
Asset Classification
- Platform-derived therapeutic
- Oncology/fibrosis expansion candidate
- High-value indication class
Value Drivers
- Large addressable markets
- Multi-indication expansion
- Strong differentiation from existing therapies
XVII. CALL TO ACTION
Expand SCF Therapeutic Pipeline
We are seeking:
- Oncology and fibrosis research partners
- Clinical development collaborators
- Strategic investors
